Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 582 studies whose lead sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. 72 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 582. Browse all 582 →
- GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent GliomaNot yet recruitingNCT07852975Not applicable
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingNCT07430202Phase 1
- DK222 Study at HopkinsRecruitingNCT07140315Phase 1
- Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse EventsNot yet recruitingNCT07836101Phase 2
- A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered GliomaRecruitingNCT06610682Early Phase 1
- PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADTRecruitingNCT07550517Phase 2
- Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic TumorsRecruitingNCT07360119Not applicable
- PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCRecruitingNCT06245889Phase 2
- Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer PatientsRecruitingNCT06138067Not applicable
- Cardiometabolic Screening ProgramRecruitingNCT05386719Not applicable
- Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)Not yet recruitingNCT07793240
- Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNot yet recruitingNCT07793253Phase 2
- Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade GliomasNot yet recruitingNCT07778602Early Phase 1
- Gut Microbiome, Adverse Effects, and Markers Through MEtabolic ReprogrammingRecruitingNCT06536881Not applicable
- Immunobiology Blood and Tissue Collection of Upper Aerodigestive MalignanciesRecruitingNCT05995821
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingNCT06411691Phase 1
- Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLCRecruitingNCT05950139Phase 1/2
- Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)RecruitingNCT07424222Phase 1
- Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal CancerNot yet recruitingNCT07580339Phase 2
- Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal CellRecruitingNCT07062549Phase 1
- Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerRecruitingNCT07281768Phase 2
- Sequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionRecruitingNCT04363164Phase 2
- Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone SarcomaRecruitingNCT06796543Not applicable
- HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical NeoplasiaRecruitingNCT04131413Phase 1
- A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer PatientsRecruitingNCT06315257Phase 1
- Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+RecruitingNCT06210854Phase 2
- Proton Radiation Therapy RegistryRecruitingNCT04376229
- Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid CancerRecruitingNCT04892303Phase 1
- 7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate CancerRecruitingNCT06826924Not applicable
- Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric PatientsRecruitingNCT05658731Not applicable
- Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder CancerRecruitingNCT05312671Phase 2
- The COSMYC Trial (COmbined Suppression of MYC)RecruitingNCT06922318Phase 2
- Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)RecruitingNCT07375992Not applicable
- Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)RecruitingNCT06564623Phase 1
- Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal CancerRecruitingNCT06205836Phase 2
- Precision Radiotherapy Enabled by Molecular MRIRecruitingNCT07512154Not applicable
- NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerRecruitingNCT06941857Phase 2
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaRecruitingNCT03521830Phase 2
- Proton SBRT for Spinal MetastasisRecruitingNCT06895564Not applicable
- Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)RecruitingNCT07209189Phase 2
- Pre-operative Hypofractionated Proton TherapyRecruitingNCT05917301Not applicable
- Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)RecruitingNCT06803745Not applicable
- Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell CarcinomaRecruitingNCT06376669Phase 2
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene MutationsRecruitingNCT03786796Phase 2
- KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLCRecruitingNCT05254184Phase 1
- SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment OptimizationRecruitingNCT06389097
- Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaRecruitingNCT07071155Early Phase 1
- Reduced Intensity Haploidentical BMT for High Risk Solid TumorsRecruitingNCT01804634Phase 2
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseRecruitingNCT07142551Phase 2